Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Neurobiol Learn Mem. 2017 Feb 16;140:52–61. doi: 10.1016/j.nlm.2017.02.004

Figure 4.

Figure 4

LY39 (0.3 mg/kg, i.p.) in vivo treatment for one hour significantly decreases the amplitude and frequency of NMDA-mEPSCs in both saline and MAM animals. A, Representative NMDA-mEPSCs for each of four groups (Sal-Sal, MAM-Sal, Sal-LY39, MAM-LY39). Saline and LY39 injections (0.3 mg/kg, i.p.) were administered one hour before slice preparation for electrophysiology. B, Histograms depicting the effect of prenatal MAM exposure on the amplitude and frequency of NMDA-mEPSCs, as well as the effect of LY39 in both saline and MAM animals following one-hour exposure. LY39 treatment significantly decreases the amplitude of NMDA-mEPSCs, regardless of group (p<0.05 for both Sal-Sal and MAM-Sal animals) but the amplitude is not affected by MAM exposure (p>0.05 vs Sal-Sal). Prenatal MAM exposure and LY39 treatment reduce the frequency of NMDA-mEPSCs compared to Sal-Sal animals, but have no statistical significance (p>0.05 for both). LY39 treatment does not affect the frequency of NMDA-mEPSCs in MAM animals (p>0.05 MAM-SAL vs. MAM-LY39).